EPZM Stock Recent News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 3